Roles
- Associate Professor of Clinical Ophthalmology
-
Education & Training
Education
-
Research Interests
Dry Eye Disease
Ocular Microbiology
High Risk Corneal Transplantation
Ocular Chemical and Thermal Burns
Cicatricial Conjunctivitis -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 2 clinical trials.
-
The purpose of this study is to find out the effectiveness of the (RGN-259) Thymosin Beta 4 eye drops solution in the clearing of a persistent epithelial defect (PED) (that is, consistent eye tissue breakdown) in subjects with Neurotrophic Keratopathy. RGN-259 is formulated as preservative-free, sterile eye drops and being studied to treat Neurotrophic Keratopathy. Since the tissue breakdown of the cornea is causing Neurotrophic Keratopathy, it is thought that this study treatment may help subjects with this disease by enhancing wound healing, repair and regeneration.
- Principal Investigator: Jaime Martinez Martinez
- Study Phase: Phase III
- Enrollment Status: Open
-
This is a double-masked, randomized, placebo-controlled, parallel-group, multi-center two-period study in subjects with Fuchs Endothelial Corneal Dystrophy (FECD) after descemetorhexis. The treatment groups consist of K-321 ophthalmic solution 0.4% four times daily (QID) and a placebo group. After the screening period and descemetorhexis procedure of the study eye on Day -1, the first period of the study is the treatment period, consisting of randomization and initiation of treatment visit and a 12-week treatment phase. The second period of the study is a 40-week follow-up period with a 2-week medication taper phase.
- Principal Investigator: Jaime Martinez Martinez
- Study Phase: Phase III
- Enrollment Status: Closed